Median annual TL change in androgen-treated and untreated participants by leukocyte subset
| Leukocyte subset . | Total granulocytes . | Total lymphocytes . | CD45+ lymphocytes . | CD45−lymphocyte . | CD20+ lymphocytes . | CD57+ lymphocyte . |
|---|---|---|---|---|---|---|
| Median annual TL change in bp (range in bp) | ||||||
| Androgen-treated | −27 (−678 to +954) | −62 (−343 to +41) | −69 (−581 to +55) | −89 (−384 to +89) | −69 (−387 to +296) | −118 (−1118 to −13) |
| Untreated | −89 (−263 to +1346) | −76 (−465 to +282) | −87 (−413 to + 55) | −52 (−51 to +130) | −79 (−413 to +27) | −62 (−404 to +279) |
| P | .66 | .71 | .96 | .96 | .79 | .32 |
| Leukocyte subset . | Total granulocytes . | Total lymphocytes . | CD45+ lymphocytes . | CD45−lymphocyte . | CD20+ lymphocytes . | CD57+ lymphocyte . |
|---|---|---|---|---|---|---|
| Median annual TL change in bp (range in bp) | ||||||
| Androgen-treated | −27 (−678 to +954) | −62 (−343 to +41) | −69 (−581 to +55) | −89 (−384 to +89) | −69 (−387 to +296) | −118 (−1118 to −13) |
| Untreated | −89 (−263 to +1346) | −76 (−465 to +282) | −87 (−413 to + 55) | −52 (−51 to +130) | −79 (−413 to +27) | −62 (−404 to +279) |
| P | .66 | .71 | .96 | .96 | .79 | .32 |